Literature DB >> 10751035

Oxidation of the N-terminal gly-residue of peptides: stress study of pexiganan acetate in a drug formulation.

B Feibush1, B C Snyder.   

Abstract

PURPOSE: The purpose of this study was to identify four major degradation products, which were formed during a stress study of pexiganan (a 22-mer peptide) in a 1% formulation.
METHODS: The degradation products were isolated and characterized by LC/MS, tryptic and aminopeptidase digests.
RESULTS: One of the degradation products was shown to be des-glyl-pexiganan. The other three are structural isomers of N-glyoxylyl-desgly1-pexiganan. These isomers undergo reversible inter-conversions, as well as decompose irreversibly to des-gly1-pexiganan. Thus, all the impurities were formed from a single oxidation product of pexiganan, N-glyoxylyl-des-gly1-pexiganan. The aldehyde group of the glyoxylyl residue and the NH-amide of the adjacent isoleucine residue form a piperazinedione derivative of des-gly1-pexiganan. This heterocyclic compound rearranges to other tautomers or back to the N-glyoxylyl compound (see Fig. 3). Tryptic digests of the three degradation products showed that their N-terminal segment produced N-glyoxylyl-I-G-K whereas the N-terminal segment of pexiganan produced G-I-G-K. All the other tryptic-digest segments were identical to those formed in pexiganan. The LC/MS of the N-terminal segment and of synthetic N-glyoxylyl-I-G-K were identical. The enzymatic resistance of the three impurities to undergo aminopeptidase-M cleavage further supported the conclusion that their N-terminal amino residues are substituted.
CONCLUSIONS: After a year under stress conditions 1% pexiganan cream lost about 15% of the active component to oxidative-deamination, where the N-terminal glycine residue was oxidized to N-glyoxylyl-desgly1-pexiganan. The other nine epsilon-amino lysine-residues of the peptide stayed intact. This oxidation product inter-converted and formed two additional impurities, tautomers of piperazinedionyl-des-gly-pexiganan, and decomposed to des-gly1-pexiganan, the forth impurity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10751035     DOI: 10.1023/a:1007521515109

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  8 in total

1.  Chemical instability of protein pharmaceuticals: Mechanisms of oxidation and strategies for stabilization.

Authors:  S Li; C Schöneich; R T Borchardt
Journal:  Biotechnol Bioeng       Date:  1995-12-05       Impact factor: 4.530

2.  Synthesis of N-glyoxylyl peptides and their in vitro evaluation as HIV-1 protease inhibitors.

Authors:  D Qasmi; E de Rosny; L René; B Badet; I Vergely; N Boggetto; M Reboud-Ravaux
Journal:  Bioorg Med Chem       Date:  1997-04       Impact factor: 3.641

3.  Synthesis of mimocin, an isoquinolinequinone antibiotic from Streptomyces lavendulae, and its congeners.

Authors:  A Kubo; Y Kitahara; S Nakahara; R Iwata; R Numata
Journal:  Chem Pharm Bull (Tokyo)       Date:  1988-11       Impact factor: 1.645

Review 4.  Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions.

Authors:  E R Stadtman
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

Review 5.  Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences.

Authors:  E R Stadtman
Journal:  Free Radic Biol Med       Date:  1990       Impact factor: 7.376

Review 6.  Potential therapeutic applications of magainins and other antimicrobial agents of animal origin.

Authors:  L Jacob; M Zasloff
Journal:  Ciba Found Symp       Date:  1994

7.  Aggregation and precipitation of human relaxin induced by metal-catalyzed oxidation.

Authors:  S Li; T H Nguyen; C Schöneich; R T Borchardt
Journal:  Biochemistry       Date:  1995-05-02       Impact factor: 3.162

8.  Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor.

Authors:  M Zasloff
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.